CRI’s CEO and Director of Scientific Affairs, Dr. Jill O’Donnell-Tormey, recently spoke with ecancer about recent developments of immunological technologies that improve patient outcomes in treatment, control, and cancer prevention.
Although the field has experienced significant progress in recent years, Dr. O’Donnell-Tormey says we can achieve further progress by, “…supporting excellent scientists, and giving them the resources they need to explore questions… this is where major leaps in our understanding and in the development of new drugs that are using your immune system will come from.”
This content was originally published on ecancer.
